SA PRO
Free Account
Themes
Eli Lilly and CompanyLLYNYSE
Loading
OverviewIntelligenceChartsNews

Analyst Sentiment

Analysts lean bullish — 85% recommend buying.

Consensus Rating
Buy
26 analysts·High coverage
85%
Rating Distribution
Strong Buy
00%
Buy
2285%
Hold
415%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Earnings & Revenue Estimates

2026E$34.27(16 analysts)
P/E44x
Current: 43.8x
Actual
Estimate
Range (Low–High)
Stock Alarm Pro
Forward Growth Estimates (YoY)
FY2027
Rev+15.88%
EPS+21.66%
FY2028
Rev+13.05%
EPS+18.48%
FY2029
Rev+9.73%
EPS+12.15%

Earnings Surprises

Beat rate:83%(10/12 quarters)
Avg surprise:+27.2%
Beat
Miss
Inline
Estimate
Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Feb 24, 2026RBC Capital
RBC Capital Starts Eli Lilly (LLY) at Outperform
Target:$1250.00
+19.9%from $1042.15
Feb 19, 2026Barclays
Eli Lilly initiated with an Overweight at Barclays
Target:$1350.00
+31.9%from $1023.22
Feb 10, 2026Loop Capital Markets
Freedom Capital Markets Upgrades Eli Lilly (LLY) to Buy
Target:$1200.00
+17.1%from $1025.00
Feb 5, 2026Scotiabank
Eli Lilly price target raised to $1,300 from $1,165 at Scotiabank
Target:$1300.00
+25.3%from $1037.13
Feb 5, 2026Truist Financial
Eli Lilly price target raised to $1,281 from $1,182 at Truist
Target:$1281.00
+24.7%from $1027.51
Feb 5, 2026Goldman Sachs
Eli Lilly price target raised to $1,260 from $1,145 at Goldman Sachs
Target:$1260.00
+13.8%from $1107.12
Feb 5, 2026Wells Fargo
Eli Lilly price target raised to $1,280 from $1,200 at Wells Fargo
Target:$1280.00
+15.6%from $1107.12
Feb 5, 2026BMO Capital
Eli Lilly price target raised to $1,300 from $1,200 at BMO Capital
Target:$1300.00
+17.4%from $1107.12
Jan 20, 2026Guggenheim
Eli Lilly price target lowered to $1,161 from $1,163 at Guggenheim
Target:$1161.00
+11.8%from $1038.40
Jan 6, 2026UBS
Eli Lilly assumed with a Buy at UBS
Target:$1250.00
+17.5%from $1064.04
Jan 5, 2026Leerink Partners
Eli Lilly (LLY) PT Raised to $1,234 at Leerink Partners
Target:$1234.00
+14.2%from $1080.36
Dec 16, 2025Daiwa
Eli Lilly upgraded to Buy from Neutral at Daiwa
Target:$1230.00
+15.7%from $1062.71
Dec 15, 2025Goldman Sachs
Eli Lilly price target raised to $1,145 from $951 at Goldman Sachs
Target:$1145.00
+10.2%from $1039.04
Dec 10, 2025HSBC
Eli Lilly price target raised to $1,070 from $850 at HSBC
Target:$1070.00
+9.0%from $981.67
Dec 4, 2025BMO Capital
Eli Lilly price target raised to $1,200 from $1,100 at BMO Capital
Target:$1200.00
+16.1%from $1033.56
Dec 3, 2025Guggenheim
Eli Lilly price target raised to $1,163 from $1,036 at Guggenheim
Target:$1163.00
+11.2%from $1046.12
Dec 2, 2025BMO Capital
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
Target:$1100.00
+3.9%from $1058.48
Dec 1, 2025National Bank
Eli Lilly price target raised to $1,286 from $950 at BofA
Target:$1286.00
+21.6%from $1057.89
Nov 24, 2025Bernstein
Eli Lilly price target raised to $1,300 from $1,100 at Bernstein
Target:$1300.00
+22.7%from $1059.70
Nov 24, 2025Morgan Stanley
Eli Lilly (LLY) PT Raised to $1,290 at Morgan Stanley
Target:$1290.00
+21.7%from $1059.70
Nov 19, 2025Truist Financial
Eli Lilly price target raised to $1,182 from $1,038 at Truist
Target:$1182.00
+12.6%from $1049.60
Nov 10, 2025Loop Capital Markets
Freedom Capital Markets Downgrades Eli Lilly (LLY) to Hold
Target:$950.00
-2.0%from $969.84
Oct 31, 2025Cantor Fitzgerald
Eli Lilly price target raised to $985 from $925 at Cantor Fitzgerald
Target:$985.00
+17.4%from $839.16
Oct 9, 2025Cantor Fitzgerald
Eli Lilly price target raised to $925 from $825 at Cantor Fitzgerald
Target:$925.00
+9.4%from $845.72
Oct 8, 2025Guggenheim
Eli Lilly price target raised to $948 from $875 at Guggenheim
Target:$948.00
+12.4%from $843.63

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance